Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2 (COVID-19 PEP)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04308668|
Recruitment Status : Recruiting
First Posted : March 16, 2020
Last Update Posted : May 1, 2020
- To test if post-exposure prophylaxis with hydroxychloroquine can prevent symptomatic COVID-19 disease after known exposure to the SARS-CoV-2 coronavirus.
- To test if early preemptive hydroxychloroquine therapy can prevent disease progression in persons with known symptomatic COVID-19 disease, decreasing hospitalizations and symptom severity.
|Condition or disease||Intervention/treatment||Phase|
|Corona Virus Infection Acute Respiratory Distress Syndrome SARS-CoV Infection Coronavirus Coronavirus Infections||Drug: Hydroxychloroquine Other: Placebo||Phase 3|
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a rapidly emerging viral infection causing COVID19. The current strategy uses a public health model of identifying infected cases, isolation, and quarantine to stop transmission. Once exposed, observation is standard-of-care. Therapy is generally not given to persons who are not hospitalized. The doses of hydroxychloroquine being used are within the normal standard FDA-approved doses.
Hydroxychloroquine may have antiviral effects against SARS-COV2 which may prevent COVID-19 disease or early preemptive therapy may decrease disease severity. This trial will use a modification of standard malaria dosing of hydroxychloroquine to provide post-exposure prophylaxis to prevent disease or preemptive therapy for those with early symptoms. People around the the United States and Canada can participate to help answer this critically important question. No in-person visits are needed.
This trial is targeting 5 groups of people NATIONWIDE to participate:
- If you are symptomatic with a positive COVID-19 test within the first 4 days of symptoms and are not hospitalized; OR
- If you live with someone who has been diagnosed with COVID-19, with your last exposure within the last 4 days, and do not have any symptoms; OR
- If you live with someone who has been diagnosed with COVID-19, and your symptoms started within the last 4 days; OR
- If you have had occupational exposure with known exposure to someone with lab-confirmed COVID-19 within the last 4 days and do not have symptoms; OR
- If you have had occupational exposure with known exposure to someone with lab-confirmed COVID-19 within the last 4 days AND have compatible symptoms starting within the last 4 days;
You may participate if you live anywhere in the United States (including territories) or in the Canadian Provinces of Quebec, Manitoba, Alberta, or Ontario.
For information on how to participate in the research trial, go to covidpep.umn.edu or email email@example.com for instructions. Please check your spam folder if you email.
In Canada, for trial information, please go to: www.covid-19research.ca
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||3000 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||Asymptomatic participants are randomized and analyzed separate from symptomatic participants.|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Post-exposure Prophylaxis or Preemptive Therapy for SARS-Coronavirus-2: A Pragmatic Randomized Clinical Trial|
|Actual Study Start Date :||March 17, 2020|
|Estimated Primary Completion Date :||May 1, 2020|
|Estimated Study Completion Date :||May 14, 2020|
Participants in this arm will receive the study drug.
200mg tablet; 800 mg orally once, followed in 6 to 8 hours by 600 mg, then 600mg once a day for 4 consecutive days
Other Name: Plaquenil
Placebo Comparator: Placebo
Participants in this arm will receive a placebo treatment.
4 placebo tablets once, followed in 6 to 8 hours by 3 tablets, then 3 tablets once-a-day for 4 consecutive days
- Incidence of COVID19 Disease among those who are asymptomatic at baseline [ Time Frame: 14 days ]Number of participants at 14 days post enrollment with active COVID19 disease.
- Overall change in disease severity over 14 days among those who are symptomatic at baseline [ Time Frame: 14 days ]Repeated Measure mixed regression model of change in: Visual Analog Scale 0-10 score of rating overall symptom severity (0 = no symptoms; 10 = most severe)
- Incidence of Hospitalization [ Time Frame: 14 days ]Outcome reported as the number of participants in each arm who require hospitalization for COVID19-related disease.
- Incidence of Death [ Time Frame: 90 days ]Outcome reported as the number of participants in each arm who expire due to COVID-19-related disease.
- Incidence of Confirmed SARS-CoV-2 Detection [ Time Frame: 14 days ]Outcome reported as the number of participants in each arm who have confirmed SARS-CoV-2 infection.
- Incidence of Symptoms Compatible with COVID19 (possible disease) [ Time Frame: 90 days ]Outcome reported as the number of participants in each arm who self-report symptoms compatible with COVID19 infection.
- Incidence of All-Cause Study Medicine Discontinuation or Withdrawal [ Time Frame: 14 days ]Outcome reported as the number of participants in each arm who discontinue or withdraw medication use for any reason.
- Overall symptom severity at 5 and 14 days [ Time Frame: 5 and 14 days ]Visual Analog Scale 0-10 score of rating overall symptom severity (0 = no symptoms; 10 = most severe)
- Ordinal Scale of COVID19 Disease Severity at 14 days among those who are symptomatic at trial entry [ Time Frame: 14 days ]Participants will self-report disease severity status as one of the following 3 options; no COVID19 illness (score of 1), COVID19 illness with no hospitalization (score of 2), or COVID19 illness with hospitalization or death (score of 3). Increased scale score indicates greater disease severity. Outcome is reported as the percent of participants who fall into each category per arm.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04308668
|Contact: David Boulware (Please email), MD, MPHfirstname.lastname@example.org|
|United States, Minnesota|
|Nationwide Enrollment via Internet, please email: email@example.com||Recruiting|
|Minneapolis, Minnesota, United States, 55455|
|Contact: David Boulware firstname.lastname@example.org|
|University of Minnesota||Recruiting|
|Minneapolis, Minnesota, United States, 55455|
|Contact: David R Boulware, MD, MPH email@example.com|
|Sub-Investigator: Matt Pullen, MD|
|Sub-Investigator: Sarah Lofgren, MD|
|Sub-Investigator: Caleb Skipper, MD|
|Sub-Investigator: Radha Rajasingham, MD|
|Sub-Investigator: Mahsa Abassi, DO, MPH|
|Sub-Investigator: Ananta Bangdiwala, MS|
|Sub-Investigator: Kathy Hullsiek, PhD|
|Sub-Investigator: Katelyn Pastick|
|Sub-Investigator: Elizabeth Okafor|
|Sub-Investigator: Nicole Engen, MS|
|Sub-Investigator: Darlisha Williams, MPH|
|United States, New York|
|New York, New York, United States, 10001|
|Contact: David Boulware, MD firstname.lastname@example.org|
|University of Alberta||Recruiting|
|Edmonton, Alberta, Canada|
|Contact: Ilan Schwartz, MD email@example.com|
|University of Manitoba||Recruiting|
|Winnipeg, Manitoba, Canada|
|Contact: Ryan Zarychanski, MD firstname.lastname@example.org|
|Contact: Lauren E Kelly, PhD email@example.com|
|Sub-Investigator: Glen Drobot, MD|
|Sub-Investigator: Lauren MacKenzie, MD|
|Sub-Investigator: Sylvain Lother, MD|
|Research Institute of the McGill University Heath Centre||Recruiting|
|Montréal, Quebec, Canada|
|Contact: Todd C Lee, MD 5149341934 ext 32965 firstname.lastname@example.org|
|Sub-Investigator: Emily G McDonald, MDCM MSc|
|Sub-Investigator: Matthew P Chang, MDCM|
|Sub-Investigator: Alek Lefebvre|
|Principal Investigator:||David Boulware, MD, MPH||University of Minnesota|